Sarafan ChEM-H
Showing 1-70 of 70 Results
-
Bria Castellano
Scientific Program Manager, Training and DEI, Sarafan ChEM-H
Current Role at StanfordChEM-H* Scientific Program Manager for Training and DEI**
*Chemistry, Engineering and Medicine for Human Health Research Institute
**Diversity, Equity and Inclusion -
Thomas J Cirino
Research Scientist, Animal Pharmacology, Innovative Medicines Accelerator (IMA)
BioIn Vivo Pharmacologist with expertise in CNS disorders including neurodegenerative disease, psychiatric disorders and pain.
-
Jean Dam
Research Scientist, Medicinal Chemistry, Innovative Medicines Accelerator (IMA)
Current Role at StanfordResearch Scientist at the MCKC
-
Marc Fleischmann
Project & Knowledge Management, Sarafan ChEM-H
Current Role at StanfordProject and Knowledge Management
-
Lynette Renae Haberman
Program Manager, Student Programs and Training, Sarafan ChEM-H
Current Role at StanfordProgram Manager, Student Programs and Training
-
Paul S Humphries
Alliance Director, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)
-
Amy Jacobson
Director of Microbiome Therapies, Microbiome Therapies Initiative (MITI)
Current Role at StanfordSenior Scientific Program Manager, Sarafan ChEM-H and Stanford Innovative Medicines Accelerator
-
Elizabeth Ponder
Executive Director, Sarafan ChEM-H
BioDr. Elizabeth Ponder joined Stanford ChEM-H in 2014 and is currently the Executive Director of Sarafan ChEM-H and the Stanford Innovative Medicines Accelerator (IMA). Dr. Ponder completed her Ph.D. and postdoctoral training at Stanford University in the laboratory of Dr. Matthew Bogyo. Her past work has included promoting public-private partnerships in the non-profit sector, managing multidisciplinary research in the higher education sector, and business development consulting in the for-profit biotech sector. Dr. Ponder joined ChEM-H from the University of California, Berkeley where she served as the Executive Director of the Henry Wheeler Center for Emerging & Neglected Diseases (CEND).
-
David Solow-Cordero
Associate Director, High-Throughput Screening, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAssociate Director, High-Throughput Screening Knowledge Center, , Sarafan ChEM-H and Innovative Medicine Accelerator (IMA)
This high-throughput screening (HTS) laboratory allows Stanford researchers and others to discover novel modulators of targets that otherwise would not be practical in industry. The center incorporates instrumentation (purchased with NCRR NIH Instrumentation grant numbers S10RR019513, S10RR026338, S10OD025004, and S10OD026899), databases, compound libraries, and personnel whose previous sole domains were in industry.
Among our instrumentation are a fully automated Molecular Devices ImageXpress Micro Confocal High-Content fluorescence microplate imager, with live cell, fluidics and phase contrast options, an Echo 655 Acoustic Dispense, a Thermo integrated HTS robotic system, a Caliper Life Sciences SciClone ALH3000 and an Agilent Bravo microplate liquid handler, and the BMG Clariostarplus, Tecan Infinite M1000 and M1000 PRO and Molecular Devices FlexStation II 384 fluorescence, luminescence and absorbance multimode microplate readers.
We have over 180,000 small molecules for compound screens, 15,000 cDNAs for genomic screens, and whole genome siRNA libraries targeting the human genome (the siARRAY whole human genome siRNA library from Dharmacon, targeting 21,000 human genes) and the mouse genome (Qiagen mouse whole genome siRNA set V1 against 22,124 genes).
The HTSKC main screening lab is located in ChEM-H W008, the cell-based assay development lab is located in CCSR Room 0133-North Wing, between the Transgenic Mouse Facility, and the Stanford Genomics Facility.
